|

Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10 Clinical Trials

2 actively recruiting trials across 1 location

Also known as: APAMISTAMAB-B10-ASTATINE AT-211, Astatine 211-Labeled Anti-CD45 Monoclonal Antibody BC8-B10, Astatine At 211 MAb BC8-B10, At 211 Anti-CD45 Monoclonal Antibody BC8-B10, At 211 MAb BC8-B10

Pipeline

Phase 1/2: 2

Top Sponsors

  • Fred Hutchinson Cancer Center2

Indications

  • Cancer2
  • Non-Malignant Neoplasm1
  • Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome1
  • Acute Lymphoblastic Leukemia in Remission1
  • Recurrent Mixed Phenotype Acute Leukemia1

Seattle, Washington2 trials

211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome

Fred Hutch/University of Washington Cancer Consortium

Phase 1/2
Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases

Fred Hutch/University of Washington Cancer Consortium

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.